Natrecor (nesiritide) - May 19, 2005

Audience: Cardiologists/cardiovascular healthcare professionals

Scios and FDA notified healthcare professionals of revisions to the ADVERSE REACTIONS/Effect on Mortality section of the prescribing information for Natrecor [nesiritide], indicated for patients with acutely decompensated congestive heart failure. The Dear Healthcare Professional letter also provided information from Scios on several published reports that raise the question of whether the product may have adverse effects on survival and kidney function compared to control agents (generally nitroglycerin and diuretics).

[May 6, 2005 - Dear Healthcare Professional Letter - Scios]
[April, 2005 - Natrecor Label - Scios]

Comments